Reynolds David S
Pfizer Global Research and Development, Sandwich, Kent, CT13 9NJ, United Kingdom.
Pharmacol Biochem Behav. 2008 Jul;90(1):37-42. doi: 10.1016/j.pbb.2008.03.015. Epub 2008 Mar 28.
The identification of gamma-aminobutyric acid A (GABA(A)) receptor subunit genes over the last twenty years has shown that GABA(A) receptors are made up of many different subtypes. As such the dissection of which receptor subtypes mediate which functions of clinically useful GABAergic drugs, such as benzodiazepines, has been extremely complicated. Two complimentary approaches have been taken: the development of subtype-selective drugs and the genetic manipulation of different receptor subunits. Both have yielded exciting results, but sometimes with contradictory findings. This review highlights the strengths and weaknesses of both approaches, illustrating with specific discussion of the work, to uncover which receptor subtype(s) mediates the anxiolytic effects of benzodiazepines.
在过去二十年中,γ-氨基丁酸A(GABA(A))受体亚基基因的鉴定表明,GABA(A)受体由许多不同的亚型组成。因此,剖析哪些受体亚型介导临床上有用的GABA能药物(如苯二氮䓬类药物)的哪些功能极其复杂。人们采取了两种互补的方法:开发亚型选择性药物和对不同受体亚基进行基因操作。两者都取得了令人兴奋的结果,但有时也会出现相互矛盾的发现。本综述强调了这两种方法的优缺点,并通过对相关工作的具体讨论进行说明,以揭示哪些受体亚型介导苯二氮䓬类药物的抗焦虑作用。